Measurement of Serum Chromogranin A Level in 56 Patients with Neuroendocrine Tumors Using Immunoradiometric Assay

#623

Introduction: More NETs have been diagnosed with the increasing awareness of the diseases, but few centers in China have introduced CgA testing as a tumor marker.

Aim(s): In this study, serum CgA levels were determined using immunoradiometric assay (IRMA) in 56 NET patients (pts) with an attempt to explore its clinical significance.

Materials and methods: A total of 56 NET pts who were treated in our hospital from June 2012 to September 2012 and 14 healthy subjects were enrolled in this study. Fasting blood samples were collected for serum CgA measurement using IRMA.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Tan H, Jia L,

Keywords: chromogranin A, neuroendocrine tumors, biomarker,

To read the full abstract, please log into your ENETS Member account.